[[(氨基羰基)氨基]羰基]草酰胺 | 71412-19-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: [[(氨基羰基)氨基]羰基]草酰胺
• 中文别名: (3R,6S)-6-(羟甲基)-3-甲基-6-壬基四氢-2H-吡喃-2-酮
• 英文名称: oxamidobiuret
• 英文别名: 1-Aminooxalyl-biuret；Oxamoyl-biuret；Amidooxalyl-biuret；{[(Aminocarbonyl)amino]carbonyl}oxamide；[[(Aminocarbonyl)amino]carbonyl]oxamide；N'-(carbamoylcarbamoyl)oxamide
• CAS: 71412-19-6
• 化学式: C₄H₆N₄O₄
• 分子量: 174.116
• InChiKey: XYISUGIJDGQPCY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.7
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  144
• 氢给体数：
  4
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  [[(氨基羰基)氨基]羰基]草酰胺 、 氢碘酸 生成 草酸
  参考文献：
  名称：

  Biltz; Topp, Chemische Berichte, 1913, vol. 46, p. 1399

  摘要：

  DOI：
• 作为产物：
  描述：

  4-ethoxyoxalyl-allophanic acid ethyl ester 在 乙醇 、 氨 作用下， 生成 [[(氨基羰基)氨基]羰基]草酰胺
  参考文献：
  名称：

  Bornwater, Recueil des Travaux Chimiques des Pays-Bas, 1913, vol. 32, p. 337

  摘要：

  DOI：

文献信息

• Functional Status and Health-Related Quality of Life of Elderly Osteoarthritic Patients Treated With Celecoxib
  作者：J. Lisse、L. Espinoza、S. Z. Zhao、S. D. Dedhiya、J. T. Osterhaus

  DOI：10.1093/gerona/56.3.m167

  日期：2001.3.1

  Background, This study evaluates the impact of celecoxib on functional status, health-related quality of life (HRQOL), and safety of elderly patients (greater than or equal to 70 years) with osteoarthritis (OA) of the knee and/or hip.Methods. Data were pooled from three prospective, randomized, multicenter, double-blind, parallel group trials, each having a 12-week treatment period. Multicenter studies were conducted in the United States and Canada. Data for patients diagnosed with active OA of the knee and/or hip in a flare state who were 70 years of age and older were included in the comparison of therapeutic doses of celecoxib or naproxen versus placebo (N = 768). Elderly patients from each of the three trials who were randomly assigned to groups treated with a placebo, 200 mg/day of celecoxib, 400 mg/day of celecoxib, or 1000 mg/day of naproxen were included in this analysis. The Western Ontario and McMaster Universities Osteoarthritis Index was used to measure functional status. The Short Form-36 was used as a general measure of HRQOL. Safety was assessed according to the incidence and type of adverse reactions as reported by the patients and the rate of withdrawal due to adverse events.Results. At the end of the treatment period. patients in the celecoxib groups had significant improvement in both functional status and HRQOL in comparison with the placebo group. The effects of total daily doses of 200 mg of celecoxib, 400 mg of celecoxib, and 1000 mg of naproxen on functioning and HRQOL were not found to be significantly different from each other. The incidence of serious adverse events and withdrawal from the studies due to adverse events were similar in the celecoxib groups as they were in the placebo group. Overall, the naproxen group reported a significantly higher incidence of gastrointestinal adverse events than did the placebo and the 200-mg-daily celecoxib groups.Conclusions. This study showed that celecoxib and naproxen significantly improved functional status and HRQOL in elderly patients compared with those treated with a placebo. Celecoxib-treated patients were also found to experience safety and tolerability similar to that of the placebo-treated patients.
• Bornwater, Recueil des Travaux Chimiques des Pays-Bas, 1916, vol. 35, p. 128
  作者：Bornwater

  DOI：——

  日期：——
• Biltz; Topp, Chemische Berichte, 1913, vol. 46, p. 1399
  作者：Biltz、Topp

  DOI：——

  日期：——
• Bornwater, Recueil des Travaux Chimiques des Pays-Bas, 1913, vol. 32, p. 337
  作者：Bornwater

  DOI：——

  日期：——